Keyphrases
Bortezomib
87%
Chemotherapy-induced Peripheral Neuropathy
73%
Neuropathy
72%
Peripheral Neuropathy
60%
Bortezomib-induced Peripheral Neuropathy
52%
Oxaliplatin
50%
Glioblastoma
45%
Protease Inhibitors
45%
Mouse Model
44%
Neurotoxicity
37%
Glioblastoma Therapy
36%
Antineoplastic Agents
31%
Peripheral Neurotoxicity
30%
Chemotherapy
30%
Adverse Events
25%
Glioblastoma Cell Lines
24%
DFF40
24%
Oxaliplatin Neurotoxicity
24%
Catechol
24%
Intranasal Administration
24%
Risk Factors
23%
Oxaliplatin-induced Neuropathy
23%
Retreatment
23%
Brain Tumor
22%
Glioblastoma multiforme
22%
Seizure
21%
Multiple Myeloma
21%
Blood-brain Barrier
20%
Colorectal Cancer Patients
19%
Peripheral Nerve
19%
Severe Neuropathy
18%
Toxic Effects
18%
Cisplatin
18%
Neuromonitoring
18%
Cerebrospinal Fluid
17%
Inflammatory Response
17%
Endonuclease
17%
Intranasal
16%
Quality of Life
16%
Taxanes
15%
Primary Sensory Neurons
15%
Hazard Ratio
14%
Pharmacogenetics
14%
Neuropathic Pain
14%
Multiple Myeloma Patients
14%
Patient Identification
14%
Brain Metastases
14%
Tumoral
13%
Dorsal Root Ganglion
13%
High Risk
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neurotoxicity
100%
Neuropathy
99%
Glioblastoma
73%
Bortezomib
60%
Chemotherapy
56%
Oxaliplatin
54%
Malignant Neoplasm
44%
Chemotherapy-Induced Peripheral Neuropathy
36%
Proteasome Inhibitor
33%
Multiple Myeloma
33%
Peripheral Neuropathy
30%
Anticarcinogen
29%
Mouse Model
27%
Adverse Event
26%
Cisplatin
25%
Catechol
24%
Nanoparticle
24%
Blood-Brain Barrier
20%
Side Effect
16%
Endonuclease
16%
Inflammation
15%
Neuropathic Pain
15%
Neoplasm
14%
Colorectal Cancer
14%
Prodrug
14%
Caspase
14%
Brain Metastasis
13%
Immunoglobulin Enhancer Binding Protein
13%
Pharmacogenetics
13%
Tumor Necrosis Factor
12%
Gossypol
12%
Sigma 1 Opiate Receptor
12%
Neuroprotection
12%
Nerve Growth Factor
12%
Taxane
12%
Immunoglobulin D
12%
Phase II Trials
12%
Non Small Cell Lung Cancer
12%
Atezolizumab
12%
Pemetrexed
12%
Carboplatin
12%
Intracranial Tumor
11%
Survival Rate
11%
Progression Free Survival
9%
Colorectal Carcinoma
9%
Anticonvulsive Agent
9%
Overall Survival
9%
Cytokine
8%
Pathophysiology
7%
Normal Human
7%
Medicine and Dentistry
Glioblastoma
49%
Neuropathy
43%
Oxaliplatin
42%
Chemotherapy-Induced Peripheral Neuropathy
36%
Neurotoxicity
36%
Chemotherapy
33%
Bortezomib
28%
Malignant Neoplasm
27%
Multiple Myeloma
27%
Cerebrospinal Fluid
26%
Anticarcinogen
25%
Peripheral Neuropathy
24%
Nanoparticle
24%
Overall Survival
18%
Adverse Event
16%
Magnetic Resonance Imaging
16%
Epileptic Seizure
16%
Neuromonitoring
15%
Colorectal Cancer
14%
Chemotherapeutic Agent
14%
Side Effect
14%
Neuropathic Pain
14%
Brain Metastasis
14%
Hazard Ratio
13%
Neoplasm
13%
Oligoastrocytoma
13%
Radiation Therapy
12%
Autonomic Nervous System
12%
Blood Brain Barrier
12%
Transitional Cell Carcinoma
12%
Meningeal Carcinomatosis
12%
Bladder
12%
Serositis
12%
Caspase
12%
Immunoglobulin D
12%
Nerve Growth Factor
12%
Immune-Related Adverse Events
12%
Shunting
12%
Proton Nuclear Magnetic Resonance
12%
Neuroprotection
12%
Lymphomatosis
12%
Sigma 1 Opiate Receptor
12%
Intranasal Drug Administration
12%
Normal Pressure Hydrocephalus
12%
Systematic Review
12%
Primary Central Nervous System Lymphoma
12%
NMR Spectroscopy
12%
Endonuclease
12%
Quantitative Sensory Testing
12%
Cell Death
12%